IMR Press / FBL / Volume 19 / Issue 4 / DOI: 10.2741/4238

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

The STAT3-Ser/Hes3 signaling axis in cancer
Show Less
1 Department of Medicine, University of Dresden, Dresden, Germany
2 Department of Neurological Surgery, University of Virginia, USA
3 Department of Medicine, University of Dresden, Dresden, Germany, and, Center for Regenerative Therapies Dresden, Dresden, Germany
Front. Biosci. (Landmark Ed) 2014, 19(4), 718–726;
Published: 1 January 2014

Disrupting the regenerative capacity of tumorigenic cells is a major focus in medicine. These regenerative properties are carried by a subpopulation of cells within the tumor, termed cancer stem cells. Current therapies don't effectively tackle the disease suggesting these cells employ yet unidentified molecular mechanisms allowing them to evade targeting. Recent observations in neural stem cells reveal an extraordinary plasticity in the signaling pathways they utilize to grow. These findings are being extended to the cancer stem cell field, illuminating conceptually novel treatment strategies. Tumorigenic cells can make use of distinct, even opposing pathways, including JAK/STAT and the non-canonical STAT3-Ser/Hes3 signaling axis. This plasticity may not be confined to the cancer stem cell population, but may be shared by various cell types within the tumor, blurring the line distinguishing cancer stem cells from other tumor cell types. The implications to anti-cancer medicine are highly significant, since these findings demonstrate that inhibiting one cell growth pathway may actually enhance the activity of alternative ones. Drug discovery programs will also benefit from these concepts.

Cancer Stem Cells
Signal Transduction
Drug Discovery
Back to top